Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00072319 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating Women With Stage I, Stage II, or Stage III Breast Cancer
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00072319: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00072319 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00072319, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy, such as epirubicin, cyclophosphamide, and paclitaxel, use different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy drugs before surgery may shrink the tumor so that it can be removed during surgery. Giving chemotherapy drugs after surgery may kill any remaining tumor cells. PURPOSE: Pilot trial to study the effectiveness of neoadjuvant or adjuvant epirubicin, cyclophosphamide, and paclitaxel in treating women who have stage I, stage II, or stage III breast cancer.
Interventions
- DRUG cyclophosphamide
- DRUG paclitaxel
- DRUG epirubicin hydrochloride
- PROCEDURE adjuvant therapy
- BIOLOGICAL filgrastim
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-08 |
| Est. Completion | 2006-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00072319
The ClinicalTrials.gov registry entry for NCT00072319 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00072319 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00072319 about?
NCT00072319 is a clinical study titled "Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating Women With Stage I, Stage II, or Stage III Breast Cancer". RATIONALE: Drugs used in chemotherapy, such as epirubicin, cyclophosphamide, and paclitaxel, use different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy drugs before surgery may shrink the tumor so that it can be removed during surgery. Giving chemotherapy d...
What is the current status of trial NCT00072319?
This trial is currently completed. It is a Phase 2 study. The study started on 2003-08. Estimated completion is 2006-11.
What interventions are being tested in trial NCT00072319?
The interventions under investigation include: cyclophosphamide (DRUG), paclitaxel (DRUG), epirubicin hydrochloride (DRUG), adjuvant therapy (PROCEDURE), filgrastim (BIOLOGICAL).
Who is sponsoring clinical trial NCT00072319?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.